Page 13 - FLIPBOOK
P. 13

Ipilimumab + Nivolumab vs Sunitinib









                                                                   INTERMEDIATE / POOR
                                                                                   RISK









































                                                                                                                                                       Albiges L, et al. ESMO Open. 2020
   8   9   10   11   12   13   14   15   16   17   18